.jpg)
Combined therapy against cancer
WO2020020942
The CNIO has developed a combined therapy against cancer inhibiting expression, activity and/or function of epidermal growth factor receptor (EGFR) and c-RAF. The inventors have found a novel pharmaceutical composition comprising an inhibitor of the expression, activity and/or function of c-Raf and an inhibitor of the expression, activity and/or function of EGF Receptor and its use in the treatment of cancer, for example, pancreatic cancer.
The inventors have shown that the simultaneous deletion of EGFR and c-Raf in pancreatic ductal adenocarcinoma (PDAC) results in a significant therapeutic effect with an extremely low toxicity. The present invention represents a very promising therapy in the treatment of pancreatic cancer since it leads to a complete tumor regression while its side effects are much smaller than other therapies described up to date.